Lebwohl, Mark (2020), "Supplement for "Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)""

Published: 18-09-2020| Version 5 | DOI: 10.17632/27h89s5wpx.5
Mark Lebwohl,
Leon Kircik ,
Jean-Philippe Lacour ,
Monika Liljedahl ,
Charles Lynde ,
Marie Holst Moerch ,
Kim A. Papp ,
Jean-Luc Perrot ,
Linda Stein Gold,
Amrit Takhar ,
Diamant Thaci,
Richard B. Warren ,
Andreas Wollenberg


Supplementary material A presents the trial design and interventions of the PSO-LONG trial. Supplementary material B provides an overview of adverse events adjudicated as related to long-term corticosteroid use. Supplementary material C details the list of Principal Investigators who supported with the study.